Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.30%
#2 Victoria VR Victoria VR +9.12%
#3 Movement Movement +8.40%
#4 COTI COTI +7.33%
#5 DMT-NAT DMT-NAT +6.93%
#6 Palladium Network Palladium Network +4.63%
#7 Prom Prom +4.55%
#8 Test Test +4.07%
#9 GRVT Token GRVT Token +3.80%
#10 Cryptopia Cryptopia +3.74%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
設定
言語
日本
通貨
USD
テーマ
Xeno Transplants Corporation Xeno Transplants Corporation

Xeno Transplants Corporation

XENO
株式のランク #42146
Xeno Transplants Corporation functions as a biotechnology firm dedicated to... Xeno Transplants Corporation functions as a biotechnology firm dedicated to research and development. Leveraging a specific licensing agreement with Massachusetts General Hospital, the company aims to innovate, produce, commercialize, and implement products and methodologies for public application in the field of xenotransplantation. The primary objective of this xenotransplantation research is to alleviate the critical scarcity of human cells, tissues, and organs required for medical transplants. This is achieved by pioneering techniques that enable the transfer of biological components—such as cells, tissues, and organs—from non-human species, including pigs, into human recipients. Established in 2004, Xeno Transplants Corporation maintains its headquarters in Brookline, Massachusetts.
株価
$0.0001
最終同期: 2026-08-11
時価総額
$4.04K
変化（1日）
0.00%
変化（1年）
0.00%
国
CA
取引 Xeno Transplants Corporation (XENO)

カテゴリー

Healthcare
Xeno Transplants Corporation（XENO）の利益
2026 時点の利益 TTM: 0
Xeno Transplants Corporation の最新の財務報告によると、同社の現在の利益は 0 です。2026 年には 0 の利益を上げ、これは 2026 年の利益 0 と 同等 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Xeno Transplants Corporation の利益の推移（2026 〜 2026）
各年末の利益
年 利益 変化
提供された日付のデータは十分ではありません。
同業他社の利益
企業 利益 利益の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR